Costas Loullis Named Vice President of R&D For Intrexon Corporation.

BLACKSBURG, Va. -- Intrexon Corporation, a life sciences company focused on the development of transcriptional therapeutics for critical human diseases, announced the appointment of Costas Loullis, Ph.D. as the Vice President of Research and Development (R&D). Dr. Loullis will be responsible for the operational aspects of the Company's R&D initiatives, including managing a large scientific team and Intrexon's therapeutic initiatives. Dr. Loullis will report directly to Intrexon's Chief Executive Officer, Robert Beech, and work collaboratively with Thomas Reed, Ph.D., Chief Science Officer, and J. Mark Braughler, Ph.D., Vice President of Translational Medicine, to advance the Company's mission.

"The addition of Dr. Loullis to our executive team is essential to the growth and productivity of our Research and Development organization," said Robert Beech, Chief Executive Officer of Intrexon. "Costas is top-tier executive with extensive experience in drug development, across all aspects of the R&D spectrum from bench to bedside."

Prior to starting with Intrexon Corporation, Dr. Loullis was the founder and president of Anixis Biomedical Consulting, providing the pharmaceutical industry with strategic planning, drug and business development services. Previously, Costas served as a key member of a number of executive management teams in biotechnology companies, including Trega Biosciences, PharmaPrint, and Ancile Pharmaceuticals, where he established and led a number of research, preclinical, development, clinical, and regulatory groups and was fully engaged in strategic planning, operations and product positioning. During an earlier period, Costas held various positions of increasing responsibility in R&D at American Cyanamid (now Wyeth) and Rhone Poulenc Rorer (now Aventis). Dr. Loullis has a doctorate in Biopsychology and was a NIMH Postdoctoral Fellow in Neurochemistry.

"I am very pleased to join a company with this caliber of innovation and science," said Dr. Costas Loullis. "As Vice President of Research and Development with Intrexon Corporation, I look forward to the excitement of working in a dynamic, growing organization. Intrexon is a company with truly innovative technology that will aid in the cure of devastating diseases. I feel fortunate to be contributing to the operational excellence of their R&D organization."

About Intrexon Corporation

Intrexon is a privately held life sciences company headquartered at the Virginia Tech Corporate Research Center in Blacksburg, Virginia, with additional R&D operations in Valley Forge, Pennsylvania. The company is focused on the research and development of transcriptional therapeutics for critical human diseases that have proven intractable for traditional drug modalities, such as metastatic cancer, cardiac failure and progressive neural disorders. Intrexon's transcriptional platform enables unparalleled control and specificity of complex gene programs, including inducible, multigenic programs that modulate specific protein-protein interactions in targeted subcellular locations. More information is available at www.intrexon.com.